Mark R Deneau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7400773/publications.pdf

Version: 2024-02-01

759233 677142 25 649 12 22 citations h-index g-index papers 25 25 25 613 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: Epidemiology and natural history. Hepatology, 2013, 58, 1392-1400.	7.3	179
2	The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology, 2017, 66, 518-527.	7.3	155
3	Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Hepatology, 2021, 73, 1061-1073.	7.3	50
4	Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis. Hepatology Communications, 2018, 2, 1369-1378.	4.3	30
5	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology, 2021, 161, 1764-1775.e5.	1.3	28
6	Treatment of primary sclerosing cholangitis in children. World Journal of Hepatology, 2019, 11, 19-36.	2.0	28
7	<i>Natural History of </i> Very Early Onset Inflammatory Bowel Disease <i>in North America: A Retrospective Cohort Study</i> Inflammatory Bowel Diseases, 2021, 27, 295-302.	1.9	25
8	The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children. Hepatology, 2021, 73, 1074-1087.	7.3	22
9	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
10	Inflammatory Bowel Disease Phenotype in Pediatric Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2016, 22, 146-150.	1.9	18
11	Natural Killer Cell Lymphoma in a Pediatric Patient With Inflammatory Bowel Disease. Pediatrics, 2010, 126, e977-e981.	2.1	15
12	Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course. Journal of Pediatrics, 2019, 209, 92-96.e1.	1.8	13
13	Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 459-464.	1.8	11
14	Post-Transplant Disease Recurrence in Pediatric PSC. Current Gastroenterology Reports, 2018, 20, 44.	2.5	10
15	Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels. Journal of Pediatrics, 2019, 215, 144-151.e3.	1.8	9
16	Colorectal Dysplasia and Cancer in Pediatric-Onset Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1067-1070.e2.	4.4	9
17	Implementing a Standardized Constipation-Management Pathway to Reduce Resource Utilization. Academic Pediatrics, 2018, 18, 957-964.	2.0	7
18	Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study. Hepatology, 2021, 74, 2047-2057.	7.3	7

#	Article	IF	CITATIONS
19	Reducing hospital admissions of healthy children with functional constipation: a quality initiative. BMJ Open Quality, 2017, 6, e000116.	1.1	6
20	Recurrence of Primary Sclerosing Cholangitis after Liver Transplantation in Children: Data from the Pediatric PSC Consortium. Gastroenterology, 2017, 152, S1063-S1064.	1.3	2
21	Neonatal cholestasis and hepatosplenomegaly caused by congenital dyserythropoietic anemia type 1: A case report. World Journal of Hepatology, 2019, 11, 477-482.	2.0	2
22	Assessing the Validity of Adultâ€derived Prognostic Models for Primary Sclerosing Cholangitis Outcomes in Children. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, e12-e17.	1.8	2
23	Ketorolac after colectomy for ulcerative colitis in children: An analysis of opioid utilization and postoperative complications. Journal of Pediatric Surgery, 2020, 55, 2393-2396.	1.6	O
24	REPLY:. Hepatology, 2021, 74, 1717-1717.	7.3	0
25	A Novel Care Model for Neonatal Intestinal Failure Patients Is Associated With Cost Savings and Improved Outcomes. Gastroenterology Research, 2019, 12, 93-95.	1.3	O